Correspondence 0001493152-24-036173 from Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD.
Date: Sept. 13, 2024 · CIK: 0001962011 · Accession: 0001493152-24-036173
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274805
Letter
Re: Kairos Pharma, Ltd.
September 13, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549-3720
Attention: Messrs. Dillon Hagius and Tim Buchmiller
Registration Statement on Form S-1
File No. 333-274805
Acceleration Request
Requested Date: September 16, 2024
Requested Time: 9:00 AM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-274805) (the “Registration Statement”) so that it may become effective at 9:00 a.m. Eastern Time on September 16, 2024, or at such time as the Registrant may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant’s behalf.
The Registrant hereby acknowledges that:
(i) should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert comments of the Commission or the Staff and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
Kairos
Pharma, Ltd.
Show Raw Text
CORRESP
1
filename1.htm
September
13, 2024
Via
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549-3720
Attention:
Messrs. Dillon Hagius and Tim Buchmiller
Re:
Kairos
Pharma, Ltd.
Registration
Statement on Form S-1
File
No. 333-274805
Acceleration
Request
Requested
Date:
September
16, 2024
Requested
Time:
9:00
AM Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Kairos Pharma, Ltd. (the “Registrant”) hereby requests
acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-274805) (the “Registration Statement”)
so that it may become effective at 9:00 a.m. Eastern Time on September 16, 2024, or at such time as the Registrant may request by telephone
to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). In addition, the Registrant
hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant’s
behalf.
The
Registrant hereby acknowledges that:
(i)
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not
foreclose the Commission from taking any action with respect to the Registration Statement;
(ii)
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective,
does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement;
and
(iii)
the Registrant may not assert comments of the Commission or the Staff and the declaration of effectiveness of the Registration Statement
as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
Kairos
Pharma, Ltd.
By:
/s/
John S. Yu
John
S. Yu, M.D.
Chief
Executive Officer
cc:
Megan
J. Penick, Esq.
Dorsey
& Whitney LLP